Shift Pharmaceuticals Holdings, Inc.
Publicly observedColumbia, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Columbia | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Shift Pharmaceuticals Holdings, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | L5YJHR8PKA96 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss
USD 37,074.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss
USD 312,239.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.